Adverse events: hospital admission · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Adverse events: ED visits · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Proportion of participants developing a new pressure ulcer · people with pressure ulcers residing in long‐term‐care facilities
It is very uncertain whether enhanced multidisciplinary team (EMDT) changes pressure ulcer incidence rate compared with usual care (very low certainty).
1 finding from 1 review
Number of pressure ulcers healed · people with pressure ulcers residing in long‐term‐care facilities
It is very uncertain whether enhanced multidisciplinary team (EMDT) changes number of pressure ulcers healed compared with usual care (very low certainty).
1 finding from 1 review
Reduction in pressure ulcer surface area · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Time to complete healing · people with pressure ulcers residing in long‐term‐care facilities
It is very uncertain whether enhanced multidisciplinary team (EMDT) changes time to complete healing compared with usual care (very low certainty).
1 finding from 1 review
Sexual quality of life · post‐prostatectomy erectile dysfunction (long‐term)
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand placebo or no treatment (moderate certainty).
1 finding from 1 review
International Index of Erectile Function ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐reported potency · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes self‐reported potency compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Erectile function · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes erectile function compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sexual quality of life · post‐prostatectomy erectile dysfunction (long‐term)
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand PDE5I (very low certainty).
1 finding from 1 review
International Index of Erectile Function ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐reported potency ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Erectile function ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · post‐prostatectomy erectile dysfunction (long‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death ‐ in all participants ‐ short term · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in all participants ‐ short term compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Death ‐ in confirmed cases of meningococcal meningitis (subgroup) · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in confirmed cases of meningococcal meningitis (subgroup) compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review